Compare Novavax Inc (NVAX) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Global X SuperDividend ETF — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while Global X SuperDividend ETF trades at $25.24. Which is the better fit depends on your goals.
| NVAX | SDIV | |
|---|---|---|
Market Cap | $1.68B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $11.19 | $26.34 |
52-Week Low | $6.22 | $22.90 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
SDIV trades at $25.07, down 0.16% with a bullish technical signal from moving averages. The ETF maintains a consistent $0.18 monthly dividend payment schedule through mid-2026, providing income stability. Recent news highlights SDIV's 9.29% yield and diversification benefits away from tech-heavy portfolios, though questions remain about dividend sustainability.
The outlook balances high income generation against sustainability concerns. Key opportunities include attractive yield in a low-rate environment and non-tech diversification, while risks center on dividend coverage and sensitivity to global economic conditions. Technical strength supports near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
